The trajectory of Sildenafil presents a nuanced case for stakeholders in the medicinal sector. While initially a blockbuster success, creating vast sums, the intellectual property lapse and the subsequent flood of generic alternatives have considerably affected revenue. This raises questions about the long-term profitability of similar drug develop